Olaparib. PARP-1 and PARP-2 inhibitor oncolytic

Drugs of the Future

Volumn 34, Issue 2, 2009, Pages 101-105

  Vasiliou, S ^a   Castaner R ^a   Botos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; COLORECTAL TUMOR; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER;

EID: 76649140500     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.02.1339522     Document Type: Article

References (33)

1. Martin, N.M.B., Smith, G.C.M., Jackson, S.P. et al. (KuDOS Pharmaceuticals Ltd.; Maybridge Ltd.). Phthalazinone derivatives. CA 2517629, EP 1633724, GB 2415430, JP 2006519837, JP 2008001718, US 2005059663, US 2006149059, US 2008200469, US 7449464, WO 2004080976.
2. Menear, K.A., Ottridge, A.P., Londesbrough, D.J. et al. (KuDOS Pharmaceuticals Ltd.). Polymorphic form of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one. US 2008146575, WO 2008047082.
3. Menear, K.A., Adcock, C., Boulter, R. et al. 4-[3-(4- Cyclopropanecarbonyl piperazine-l-carbonyl)-4-fluorobenzyl]-2H-phthalazin-l-one: A novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 2008, 51(20): 6581-91.
4. Drew, Y., Calvert, H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann NY Acad Sci 2008, 1138: 136-45.
5. Bryant, H.E., Helleday, T. Poly (ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 2004, 32(Pt. 6): 959-61.
6. Helleday, T., Bryant, H.E., Schultz, N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005, 4(9): 1176-8.
7. Schreiber, V., Dantzer, F., Ame, J.C, de Murcia, G. Poly (ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol 2006, 7(7): 517-28.
8. Bryant, H.E., Schultz, N., Thomas, H.D. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434(7035): 913-7.
9. Evers, B., Drost, R., Schut, E. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008, 14(12): 3916-25.
10. Dungey, F.A., Chalmers, A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: Mechanisms and therapeutic potential. Int J Radiât Oncol Biol Phys 2008, 72(4): 1188-97.
11. Weston, V., Baker, C., Austen, B., Taylor, M., Moss, P., Stankovic, T. The novel PARP inhibitor, AZD2281, targets apoptotic resistant ATM mutant CLL tumours for cellular killing. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 2110.
12. Rottenberg, S., Jaspers, J.E., Kersbergen, A. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008, 105(44): 17079-84.
13. Fong, P.C., Boss, D.S., Carden, C.P. et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 5510.
14. Yap, T.A., Boss, D.S., Fong, P.C. et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3529.
15. Kaye, S., De Bono, J., Judson, I., Scurr, M., Banerji, U. New drug treatment for cancer in 2007 - Real progress at last? Eur J Cancer [14th Eur Cancer Conf (ECCO) (Sept 23-27, Barcelona) 2007] 2007, 5(4): Abst 126.
16. Phase I comparative bioavailability study (NCT00777582). ClinicalTrials.gov Web site, February 11,2009.
17. Phase I/II AZD2281/cisplatin in neoadjuvant treatment of triple negative breast cancer patients (NCT00782574). ClinicalTrials.gov Web site, February 11, 2009.
18. Dose-finding study comparing efficacy and safety of a PARP inhibitor against Doxil in BRCA+VE advanced ovarian cancer (ICEBERG 3) (NCT00628251). ClinicalTrials.gov Web site, February 11, 2009.
19. Phase I/II study of AZD2281 given in combination with paclitaxel in metastatic triple negative breast cancer (NCT00707707). ClinicalTrials.gov Web site, February 11, 2009.
20. Phase II study of AZD2281 in known BRCA or recurrent high grade ovarian cancer or known BRCA/triple NEG breast cancer (NCT00679783). ClinicalTrials.gov Web site, February 11, 2009.
21. Assessment of efficacy of AZD2281 in platinum sensitive serous ovarian cancer (NCT00753545). ClinicalTrials.gov Web site, February 11, 2009.
22. Study to assess safety & tolerability of AZD2281 in combination with bevacizumab in patients with advanced solid tumours (NCT00710268). ClinicalTrials.gov Web site, February 11, 2009.
23. AZD2281, cisplatin, and gemcitabine in treating patients with unresectable or metastatic solid tumors (NCT00678132). ClinicalTrials.gov Web site, February 11, 2009.
24. AZD2281 and carboplotin in treating patients with BRCA1/BRCA2- associated or hereditary metastatic or unresectable breast and/or ovarian cancer (NCT00647062). ClinicalTrials.gov Web site, February 11, 2009.
25. AZD2281 and irinotecan in treating patients with locally advanced or metastatic colorectal cancer (NCT00535353). ClinicalTrials.gov Web site, February 11, 2009.
26. Open label, dose escalation phase I study of AZD2281 (NCT00572364). ClinicalTrials.gov Web site, February 11, 2009.
27. Study to assess the safety & tolerability of a PARP inhibitor in combination with gemcitabine in pancreatic cancer (NCT00515866). ClinicalTrials.gov Web site, February 11, 2009.
28. A study to assess the safety and pharmacokinetics of an inhibitor of poly ADP-ribose polymerase-1 (PARP) (NCT00516373). ClinicalTrials.gov Web site, February 11, 2009.
29. Study to assess the safety and tolerability of a PARP inhibitor in combination with topotecan (NCT00516438). ClinicalTrials.gov Web site, February 11, 2009.
30. Study to assess the safety and tolerability of a PARP inhibitor in combination with corboplatin (NCT00516724). ClinicalTrials.gov Web site, February 11, 2009.
31. A study to assess the safety and pharmacokinetics of an inhibitor of PARP in combination with dacarbazine (NCT00516802). ClinicalTrials.gov Web site, February 11, 2009.
32. Study to assess the efficacy and safety of a PARP inhibitor for the treatment of BRCA-positive advanced ovarian cancer (ICEBERG 2) (NCT00494442). ClinicalTrials.gov Web site, February 11, 2009.
33. Study to assess the efficacy and safety of a PARP inhibitor for the treatment of BRCA-positive advanced breast cancer (ICEBERG 1) (NCT00494234). ClinicalTrials.gov Web site, February 11, 2009.